The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Just where do you dreamers come up with leap is a £100 million asset
It isn't
And you do more damage suggesting it is
Lead to believe the pre rto book closes friday
The CiiTECH RTO is now LIVE
Join Zoom Meeting
https://zoom.us/j/95008118382?pwd=UTNXZmN0UDhkQTJnWWlrSlE5S0t6QT09&from=addon
CiiTECH Investment Highlights
1. Trusted branded cannabis healthcare company with high-quality brands in market
o PROVACAN: CiiTECH's flagship brand, is a leading CBD brand in the UK and loved in over 100 countries, with over 75k customers.
o IMPACT: CBD sports brand for high-impact athletes. Key market: South Africa.
o HUGG: CBD cosmetics brand for women.
2. Early mover advantage in fast-growing UK CBD market [1]
o Over £7m revenue generated in UK since inception in 2018.
o Demand for CBD soars during lockdown as UK market in 2021 now estimated at £690m up from previous £526m estimate and up over 2x from £314m in 2019.
o UK has become world’s 2nd largest consumer cannabinoid market, after the US.
o UK spends more on cannabis extracts than Vitamin B & C combined.
3. Strong development pipeline
o Launching PROVACAN THC Medical Cannabis products in Israel in Q1 2022. Followed by UK rollout Q2/Q3 2022.
o LABOTANIX: Q2 launch in UK. Value CBD brand.
o PROPAWS: Q3 launch in South Africa. CBD for pets.
o PROVACAN Terpene Tincture: COVID treatment oil, developed in conjunction with Technion Israel Institute of Technology.
4. Asset-light model
o CiiTECH develops and controls its brands & IP.
o CiiTECH manages their proprietary B2C & B2B sales platforms.
o Outsourced operations: ingredients supply, packaging, product supply & logistics.
5. Global footprint with agile market entry
o UK: initial and largest market & Top Co.
o Israel: R&D centre - JV with Hebrew University & Multidisciplinary Centre for Cannabinoid Research. Patent application made for potential to treat obesity & diabetes.
o Brazil: Compassionate use for CBD - over 1,000 prescriptions fulfilled in 2020.
o South Africa: strong Rugby ties. Ambassadors: Frankie Horn & Naas Botha. Rugby Clubs including Pirates.
6. Robust, diversified approach to regulation
o Full compliance with Novel Foods in the UK.
o Every CiiTECH supplier seeking Novel Food validation, mitigating risk.
o UK has the most evolved regulatory framework (Food Standards Agency) in the world for CBD, creating a significant moat for highly compliant players like CiiTECH.
7. Proven CBD wellness execution with strong financial performance
o £3m revenue generated in 2020.
8. Strong, Management team with deep experience in cannabinoids & regulated industries
o Chairperson Nava Sofer, over 30 years of international business experience in Europe, the US, Canada, Israel, and Asia.
o Founder & CEO, Clifton Flack, has 25 Years Senior & C-Level Marketing positions. Formerly McCann Erickson & CannaTech Co-Founder.
o CFO, Steve Graubart (CFA), 40 years Senior & C-Level Finance & Venture positions. Ven
sorry 5pm
Ciitech management presentation 6pm Monday. Just had an email to confirm
things starting to happen
What on earth are you talking about
What on earth are you talking about
A New Zealand-based supplier of upmarket mixers that is aiming to establish itself as a global No 2 to Fever-Tree Drinks is set to list on Aim with a market value of £30 million.
East Imperial, founded in 2012 by Tony Burt, a former chief executive of M&C Saatchi New Zealand, is listing by means of a reverse takeover of Bermele, a cash shell, in which Burt, 50, will emerge with a 21.4 per cent stake.
Alongside the listing, East Imperial, which is being advised by Optiva Securities, a boutique broker, will raise £3 million of new funds through a placing of 30 million shares at 10p a share to finance its growth ambitions.
A New Zealand-based supplier of upmarket mixers that is aiming to establish itself as a global No 2 to Fever-Tree Drinks is set to list on Aim with a market value of £30 million.
East Imperial, founded in 2012 by Tony Burt, a former chief executive of M&C Saatchi New Zealand, is listing by means of a reverse takeover of Bermele, a cash shell, in which Burt, 50, will emerge with a 21.4 per cent stake.
Alongside the listing, East Imperial, which is being advised by Optiva Securities, a boutique broker, will raise £3 million of new funds through a placing of 30 million shares at 10p a share to finance its growth ambitions.